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Summary
Background.— In-stent restenosis remains the major limitation of percutaneous coronary inter-
vention (PCI), particularly after bare-metal stent (BMS) implantation. Drug-eluting stents (DES)
decrease in-stent restenosis, which is thought to have minimal clinical consequences, but mayBare-metal stent;
Drug-eluting stent
increase the risk of stent thrombosis and its attendant high mortality rate.
Aims.— To assess the clinical consequences of in-stent restenosis, including severity of
associated illness and acute and 1-year outcomes and to compare DES and BMS in-stent
restenosis.
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ment à un an est plus important que celui attendu dans le cadre d’une angioplastie programmée.
Pour un niveau de risque cardiovasculaire identique, il semble que le RIS post-DES ait un
pronostic discrètement inférieur à celui de la RIS post-BMS.
© 2009 Elsevier Masson SAS. Tous droits réservés.
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MS bare-metal stent
ES drug-eluting stent
SR in-stent restenosis
ACE major adverse cardiac events
I myocardial infarction
CI percutaneous coronary intervention
VR target-vessel revascularization
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nackground
ince the ﬁrst clinical angioplasty by Gruntzig in 1977 [1]
nd despite improved procedural equipment and pharma-
otherapy [2], restenosis has been the primary drawback
f PCI [3]. The introduction of stents [4] proved to be aA. De Labriolle et al.
Methods.— Using our prospective PCI registry, we compared data from 1958 consecutive
patients hospitalized with BMS in-stent restenosis between January 2000 and April 2003 and
all 190 patients with DES in-stent restenosis admitted between April 2003 and September 2006.
Risk-adjusted outcomes were calculated using propensity-score matching.
Results.— An unstable presentation was noted in 78.1% of 2148 patients. Patients with DES
in-stent restenosis presented more often with acute myocardial infarction (4.3% versus
1.6%, p < 0.001). At 1 year, mortality for all patients was 5.7% and target-vessel revascular-
ization was 21.5%. After risk adjustment, target-vessel revascularization and target-vessel
revascularization-major adverse cardiac events were greater in patients with DES in-stent
restenosis (respectively, 27.8% versus 19.7%, p = 0.05; 32.5% versus 24.3%, p = 0.06).
Conclusion.— In-stent restenosis is associated with unstable presentation and a higher 1-year
adverse events rate than expected in patients undergoing elective PCI. For an identical level of
cardiac risk, it seems that DES in-stent restenosis outcomes are slightly worse than BMS in-stent
restenosis outcomes.
© 2009 Elsevier Masson SAS. All rights reserved.
Résumé
Contexte.— La restenose intrastent (RIS) reste une limitation majeure de l’angioplastie coro-
naire, particulièrement en cas d’implantation d’un stent nu (BMS). Les stents actifs (DES)
diminuent la RIS, mais pourraient augmenter le risque de thrombose notamment tardive qui
est associée à une morbimortalité importante. Les conséquences cliniques de la RIS, supposées
minimes, ont conduit certains à penser que la diminution du risque de RIS avec les DES ne
compense pas l’augmentation du risque de thrombose.
But.— Le but de ce travail était d’évaluer les conséquences de la RIS tant dans sa présentation
clinique initiale que dans le pronostic à un an (après prise en charge de cette RIS par angio-
plastie). De plus, l’objet de ce travail était de comparer les différences entre RIS de BMS et de
DES.
Méthodes.— À partir de notre registre prospectif d’angioplastie, nous avons comparé
1958 patients consécutifs hospitalisés entre janvier 2000 et avril 2003 pour le traitement d’une
RIS post-BMS à 190 patients consécutifs hospitalisés entre avril 2003 et septembre 2006 pour
traitement d’une RIS post-DES. Le pronostic à un an a été étudié après ajustement des deux
populations par un propensity-score.
Résultats.— Une présentation instable était notée chez 78,1 % des 2148 patients avec RIS. Ceux
avec une RIS post-DES avaient plus fréquemment un infarctus du myocarde à l’admission (4,3 %
versus 1,6 % ; p < 0,001). À un an, pour les patients des deux groupes, la mortalité à un an
était de 5,7 % et le TVR de 21,5 %. Après ajustement, TVR et TVR-MACE étaient plus importants
en cas de restenose post-DES (respectivement, 27,8 % versus 19,7 % ; p = 0,05, 32,5 % versus
24,3 % ; p = 0,06) probablement lié à un excès de thrombose de stent précoce dans le groupe
RIS post-DES.
Conclusion.— La RIS a souvent une présentation instable et le taux d’évènements après traite-igniﬁcant advance in reducing the frequency of resteno-
is, by retarding elastic recoil and negative remodelling at
he treatment site [5]. Stents, however, failed to reduce
eointimal hyperplasia [6]. The next advance, the DES, was
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designed to retard or eliminate this vascular response to
injury. The use of the DES has led to a further substantial
reduction in restenosis, but not to its elimination [7—10].
A further concern has been raised: data suggest that DES
deployment is complicated by stent thrombosis, more often
than is the case with BMS deployment [11].
Some have argued that ISR after BMS deployment is a rel-
atively benign process characterized by the recurrence of
anginal symptoms, thereby offering little immediate threat
to patients. In contrast, the more frequently occurring stent
thrombosis, with its often-catastrophic consequences fol-
lowing DES deployment, may detract from the advantage
conferred by the reduced rate of restenosis [12,13]. No ﬁrm
conclusion can be reached, since more recent studies sug-
gest that BMS ISR may not be as benign as once thought
and can result in an acute coronary syndrome [14,15].
In fact, because of the infrequency of ISR following DES
deployment, little is known about its clinical characteris-
tics.
This study was designed with two goals in mind. First,
we sought to reevaluate whether or not ISR is a signiﬁcant
concern after PCI. Next, we sought to compare the clinical
syndrome produced by ISR following DES deployment with
that produced after BMS use and to compare the outcomes
of PCI in patients with BMS ISR and DES ISR.
Patients and methods
Data collection and study population
The data were extracted from our catheterization labo-
ratory registry in compliance with the provisions of the
Health Insurance and Portability Act of 1996 under a waiver
granted by the MedStar Research Institute’s institutional
review board. All patients with DES ISR treated with PCI
between April 2003 and September 2006 were compared
with all patients with BMS ISR treated between January
1999 and April 2003. Both paclitaxel-coated DES (Taxus,
Boston Scientiﬁc Corp., Natick, MA, USA) and sirolimus-
coated DES (Cypher, Johnson and Johnson Cordis Corp.,
Warren, NJ, USA) were included. Patients presenting with
stent thrombosis at the index angiogram were excluded.
These data were obtained from hospital chart review by
independent research personnel blinded to the study objec-
tives. All data management, analysis and follow-up were
performed by a dedicated data-coordinating centre (Data
Center, Cardiovascular Research Institute, Washington, DC,
USA).
Deﬁnitions
ISR was deﬁned as greater than 50% luminal diameter steno-
sis by coronary angiography located within a previously
stented arterial segment or within 5mm proximal or dis-
tal to the stent, as identiﬁed from an angiogram performed
after the index procedure. Angiographic success was deﬁned
as a thrombolysis in myocardial infarction grade 3 ﬂow post-
procedure, with a residual stenosis less than 30%. Unstable
angina was deﬁned as new-onset chest pain at rest or
increase in severity of previously stable angina (an increase
of ≥ 1 grade in Canadian Cardiovascular Society score).
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-wave and non-Q-wave MI were deﬁned as a total creati-
ine kinase elevation greater or equals to 3 times upper limit
f vulnerability and/or CK-MB greater or equals to 2 timesup-
er limit of vulnerability plus new pathological Q-waves in at
east two contiguous leads. TVR was deﬁned as repeat percu-
aneous or surgical revascularization of the treated vessel.
ll were clinically driven. MACE were deﬁned as all-cause
ortality, Q-wave MI or TVR. Stent thrombosis was deﬁned
s angiographic evidence of thrombus in the target lesion
ess or equals to 360 days from the index treatment of the
SR.
nterventional strategies and adjunctive
edical therapy
CI was performed using conventional techniques. Differ-
nces in the treatment strategy between the patient groups
ere evident following the evolution of the material and of
he guidelines. Finally, the interventional strategy regarding
he ISR lesion was left entirely to the discretion of the oper-
tor. Revascularization of another narrowed segment of the
arget vessel or another vessel during the same procedure
as performed as required.
All patients were treated with aspirin 325mg before PCI
nd loaded with clopidogrel 300 to 600mg if not already on
maintenance dose. During PCI, patients received either
ivalirudin (a bolus of 0.75mg/kg, followed by an intra-
enous infusion of 1.75mg/kg/h) or unfractionated heparin
a bolus of 40 U/kg and additional heparin to achieve an
ctivated clotting time of 250 to 300 s). Use of adjunctive
evices and platelet glycoprotein IIb/IIIa inhibitors was at
he discretion of the operator. After PCI, dual antiplatelet
herapy was recommended for four weeks in those receiving
MS and for greater or equals to six months in those treated
ith DES. Clinical follow-up was conducted by telephone
ontact or ofﬁce visit at 1 year. All events were conﬁrmed
ith source documentation. Only the index artery was con-
idered in calculating TVR.
tatistics
omparisons of clinical, procedural and outcome variables
or DES and BMS patients are presented. Continuous vari-
bles are reported as mean± S.D. and compared using the
tudent’s t test. Categorical variables are expressed as per-
entages and compared by means of contingency tables.
ifferences were tested with either the chi-square or the
isher’s exact test. A p value less than 0.05 was considered
o indicate statistical signiﬁcance. Statistical analysis was
erformed using SAS version 9.1 (SAS Institute, Cary, NC,
SA).
Because of the variations in the baseline characteris-
ics of the two cohorts, we performed a risk adjustment
alculation by means of propensity-score matching. The
ropensity score was estimated from a non-parsimonious
ogistic regression model. The following variables were
ntered into the model: cardiovascular risk factors (male,
ge, diabetes, hypertension, hypercholesterolaemia, cur-
ent smoking, body mass index), medical history (prior MI,
rior coronary artery bypass, prior chronic heart failure,
rior chronic renal insufﬁciency, prior peripheral vascu-
ar disease), clinical presentation (stable angina, unstable
2 A. De Labriolle et al.
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ngina, acute MI), and angiographic data (left anterior
escending, saphenous vein graft lesion). No interactions
ere considered in this model. The median propensity
core in the DES ISR group was 0.124 (interquartile range:
.081—0.197) and in the BMS ISR group was 0.073 (interquar-
ile range: 0.025—0.116). One patient with DES ISR was then
atched with two BMS ISR patients based on their propensity
core using the nearest available pair matching method, by
ersonnel blinded to patient outcomes. Quintiles were well
atched for important variables, particularly those estab-
ished to be predictive of stent thrombosis. The Hosmer and
emeshow goodness-of-ﬁt test was used to assess the model
o ﬁt to the data. The Chi-square test statistic was 10.3
p = 0.24), which indicates a good ﬁt of the model to the
ata. The c-statistic for the model was 0.729, indicating
ood discrimination.
esults
aseline characteristics and clinical
resentation
etween January 2000 and September 2006, a total of
148 patients were admitted for treatment of ISR. One thou-
and nine hundred and ﬁfty-eight patients had PCI of BMS ISR
nd 190 had PCI of DES ISR. Complete follow-up data for
ajor clinical events were obtained in 90% of the overall
ohort.
Baseline clinical characteristics are listed in
able 1, Plot A. Numerous differences were present.
atients with DES ISR were more often female, more often
eported hypertension, diabetes, hypercholesterolaemia
nd prior chronic heart failure, their body mass index was
reater and they more often had serum creatinine greater
r equals to 2.0mg/L or were being treated for kidney
isease.
In the overall population, 78.1% presented with unsta-
le angina, 1.8% with acute MI and 20.1% with stable
ngina. Compared with patients with BMS ISR, patients with
ES ISR presented more frequently with MI (4.3% versus 1.6%,
< 0.001) and stable angina pectoris (30.9% versus 19.1%,
< 0.001) (Fig. 1).
ngiographic and procedural
haracteristics
able 2 compares the angiographic and procedural fea-
ures for patients with DES and BMS ISR. Saphenous vein
rafts were less often the target for treatment of DES
SR and the degree of luminal narrowing was slightly less
n that cohort. Differences in treatment strategy between
he patient groups are clear. Patients with BMS ISR were
ore frequently restented, most often with another BMS.
n patients with DES ISR who were restented, a second DES
as most often deployed. The use of a cutting balloon and
f a rotablator declined between the time frames of the
wo cohorts, resulting in less frequent use of the devices
n DES ISR patients. Brachytherapy use was also less fre-
uent in these patients. The use of IIb/IIIa platelet inhibitors
H
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1igure 1. Clinical presentation of in-stent restenosis (ISR).
as more frequent in the BMS ISR group (9.5% versus 4.3%,
= 0.01). Despite these differences in treatment strategies,
he angiographic success was very high in both groups.
utcome
nadjusted outcome
nadjusted outcome is presented in Table 3, Plot A. During
ollow-up, 122 patients (5.7%) died. Fourteen patients (0.7%)
ad a Q-wave MI and 8 (0.4%) had an acute stent thrombosis.
VR was performed in 460 patients (21.5%). All major cardiac
vents (TVR-MACE) concerned 562 patients (26.3%).
In-hospital results between the two patient cohorts were
ot different and the all-cause mortality and Q-wave MI
ates were similar up to 1 year. On the other hand, by
0 days, patients with DES ISR had experienced more TVR
5.3% versus 2.4%, p = 0.02), more MACE (7% versus 3.7%,
= 0.02) and more stent thrombosis (1.6% versus 0.2%,
= 0.01) than those in the BMS ISR cohort. Between 30 days
nd 1 year, only one additional stent thrombosis was encoun-
ered in each group. Thus, while the preponderance of stent
hrombosis in the DES ISR cohort persisted through 1 year
2.1% versus 0.2%, p = 0.003), the two groups were otherwise
imilar with regard to late outcomes.
djusted outcomes
o adjust for differences in baseline characteristics and
heir potential impact on outcome, we developed an analy-
is of outcomes after propensity-score matching of the two
ohorts on baseline characteristics (Table 3, Plot B). Details
f propensity-score matching are provided in the Section
atients and methods.
The long-term clinical outcomes for the two cohorts after
atching for baseline were very similar (Table 1, Plot B).
owever, some differences in management of patients
n relation to the evolution of material and guidelines
emained (Table 2, Plot B). Therefore, for an identical
evel of cardiovascular risk, there were no differences to
year in adverse events, with the exception of more TVR
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restenosis
in
PCI
213
Table 1 Clinical and angiographic characteristics of the population.
Non-matched cohort (Plot A) Matched cohort (Plot B)
BMS ISR (n = 958) DES ISR (n = 190) Total ISR (n = 2148) p BMS ISR (n = 306) DES ISR (n = 153) p
Cardiovascular risk factors
Age (years) 62.9± 11 63.0± 11 62.9± 11.0 0.9 62.5± 10.1 62.8± 10.9 0.7
Men 1355 (69.2) 119 (62.6) 1474 (68.7) 0.06 187 (61.1) 97 (63.4) 0.6
History of smoking 1154 (58.7) 104 (54.7) 1258(58.7) 0.3 190 (62.1) 81 (52.9) 0.06
Hypertension 1423 (72.6) 175 (92.1) 1598 (74.3) <0.001 288 (94.1) 144 (94.1) 1.0
Diabetes 721 (37.0) 81 (43.1) 802 (37.5) 0.10 115 (37.6) 64 (41.8) 0.3
Hypercholesterolaemia 1657 (84.8) 182 (95.8) 1839 (85.7) <0.001 296 (96.7) 147 (96.1) 0.7
Body mass index 28.9± 5.7 30.1± 6.9 29.0± 5.87 0.01 30.0± 6.2 29.8± 6.4 0.7
Medical history
Renal insufﬁciency 166 (8.7) 31 (16.4) 197 (9.4) <0.001 40 (13.1) 20 (13.1) 1.0
Prior MI 1044 (55.8) 77 (42.5) 1121 (54.7) <0.001 137 (44.8) 69 (45.1) 0.9
Prior coronary artery bypass surgery 967 (49.6) 77 (41.0) 1044 (48.9) 0.02 129 (42.2) 63 (41.2) 0.8
Prior congestive heart failure 261 (14.1) 31 (16.7) 292 (14.3) 0.3 50 (16.3) 25 (16.3) 1.0
Clinical presentation
Stable angina 371 (19.1) 58 (30.9) 429 (20.1) <0.001 79 (25.8) 43 (28.1) 0.6
Unstable angina 1556 (79.3) 124 (64.8) 1680 (78.1) 217 (70.9) 105 (68.6)
Acute MI 31 (1.6) 8 (4.3) 39 (1.8) 10 (3.3) 5 (3.3) 1.0
Angiographic characteristics
Left ventricular ejection fraction 0.47± 0.13 0.47± 0.14 0.47± 0.13 0.8 0.48± 0.12 0.48± 0.11 0.8
Number of vessels diseased 2.0± 0.9 1.9± 0.8 1.9± 0.9 0.2 1.9± 0.8 1.8± 0.8 0.7
Percentage in-stent renarrowing 0.86± 0.1 0.86± 0.1 0.83± 0.1 <0.001 0.86± 0.1 0.83± 0.1 0.004
Angiographic success 1899 (97.6) 188 (99.6) 2087 (97.1) 0.05 362 (97.3) 180 (100.0) 0.03
IIb/IIIa inhibitor use 184 (9.5) 8 (4.3) 192 (9.1) 0.01 29 (9.6) 4 (2.7) 0.008
Quantitative variables are presented as mean± S.D. and qualitative variables are presented as n (%).
p-values refer to the comparison between BMS ISR and DES ISR.
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Table 2 Angiographic and procedural features relative to the ISR lesions.
Non-matched cohort (Plot A) Matched cohort (Plot B)
ISR Lesion as unit Total ISR (n = 2649) BMS ISR (n = 2428) DES ISR (n = 221) p BMS ISR (n = 380) DES ISR (n = 180) p
In-stent restenosis location
Left anterior descending artery lesion 662 (25.0) 594 (24.5) 68 (30.8) 0.03 116 (30.5) 65 (36.1) 0.2
Right coronary artery lesion 784 (29.6) 706 (29.1) 78 (35.3) 0.05 124 (31.2) 63 (34.8) 0.4
Left circumﬂex artery lesion 554 (20.9) 515 (21.2) 39 (17.6) 0.2 87 (22.9) 34 (18.9) 0.2
Saphenous vein graft 534 (20.2) 507 (20.9) 27 (12.2) <0.001 46 (12.1) 21 (11.7) 0.9
In stent re-narrowing 0.86± 0.13 0.86± 0.11 0.83± 0.12 <0.001 0.86± 0.13 0.83± 0.09 0.004
Stented length/lesion 20.22± 6.6 20.9± 6.34 19.2± 6.9 0.03 21.6± 6.34 18.6± 6.9 0.02
Stent diameters 3.05± 0.60 3.09± 0.7 3.0± 0.3 0.18 3.03± 0.3 2.99± 0.3 0.44
Bare-metal stent 641 (24.2) 520 (32.2) 121 (5.5) <0.001 128 (33.7) 9 (5.1) <0.001
Rotablator 50 (1.9) 50 (2.0) 0 0.01 1 (1) 0 1.0
Cutting balloon 826 (31.2) 680 (34.6) 50 (22.6) 0.09 135 (35.7) 38 (21.1) 0.001
Brachytherapy 800 (30.2) 774 (31.9) 57 (25.8) 0.06 73 (19.4) 43 (23.9) 0.228
Angiographic success 2533 (97.8) 2312 (97.6) 221 (100.0) 0.008 362 (97.3) 180 (100.0) 0.003
Patient as unit Total ISR (n = 2148) BMS ISR (n = 1958) DES ISR (n = 190) p BMS ISR (n = 306) DES ISR (n = 153) p
No. of lesions treated 1.6± 0.9 1.6± 0.9 1.7± 0.8 0.4 1.73± 1.0 1.68± 0.83 0.6
Glycoprotein IIb/IIIa use* 192 (9.1) 184 (9.5) 8 (4.3) 0.01 29 (9.6) 4 (2.7) 0.008
Drug-eluting stent 271 (12.5) 159 (8.05) 112 (58.9) <0.001 36 (11.7) 93 (60.8) <0.001
Number of stents/patient 1.21± 1.04 1.48± 0.99 0.95± 1.02 <0.001 1.48± 0.78 0.95± 0.98 0.002
Quantitative variables are presented as mean± S.D. and qualitative variables are presented as n (%).
p-values refer to the comparison between BMS ISR and DES ISR.
The procedural characteristics are presented with ISR lesion as unit.
The average number of ISR lesions per patient was 1.24 in patients with BMS ISR and 1.16 in patients with DES ISR.
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Table 3 In-hospital, 30-day and 1-year outcomes of the population.
Non-matched cohort (Plot A) Matched cohort (Plot B)
BMS ISR (n = 1958) DES ISR (n = 190) Total ISR (n = 2148) p BMS ISR (n = 306) DES ISR (n = 153) p
In-hospital outcome, n (%)
Death 19 (1.0) 1 (0.5) 20 (0.9) 1.0 3 (1.0) 0 0.5
Q-wave MI 13 (0.7) 0 13 (0.7) 0.6 3 (1.0) 0 0.5
TVR 30 (1.6) 6 (3.2) 36 (1.7) 0.1 3 (1.0) 4 (2.6) 0.2
MACE 65 (3.3) 8 (4.2) 73 (3.4) 0.5 7 (2.3) 5 (3.3) 0.5
Cumulative stent thrombosis 1 (0.1) 0 1 (0.0) 1.0 0 0 1.0
30-day outcome, n (%)
Death 24 (1.2) 3 (1.6) 27 (1.3) 0.5 5 (1.6) 1 (0.7) 0.6
Q-wave MI 8 (0.4) 1 (0.5) 9 (0.4) 0.5 1 (0.3) 1 (0.7) 0.5
TVR 47 (2.4) 10 (5.3) 57 (2.7) 0.02 7 (2.3) 8 (5.3) 0.1
MACE 72 (3.7) 13 (7) 85 (4) 0.02 12 (3.9) 10 (6.6) 0.2
Cumulative stent thrombosis 3 (0.2) 3 (1.6) 6 (0.3) 0.01 0 2 (1.3) 0.2
1-year outcome, n (%)
Death 111 (5.7) 11 (5.9) 122 (5.7) 0.9 17 (5.6) 6 (4.2) 0.4
Q-wave MI 13 (0.7) 1 (0.5) 14 (0.7) 1.0 1 (0.3) 1 (0.7) 0.5
TVR 414 (21.2) 46 (24.6) 460 (21.5) 0.2 60 (19.7) 42 (27.8) 0.05
MACE 505 (25.9) 57 (30.5) 562 (26.3) 0.1 74 (24.3) 49 (32.5) 0.06
Cumulative stent thrombosis 4 (0.2) 4 (2.1) 8 (0.4) 0.003 0 3 (2.0) 0.03
p-values refer to the comparison between BMS ISR and DES ISR.
Major adverse cardiac events (MACE) were death, Q-wave myocardial infarction (MI) and target vessel revascularization (TVR) of the ISR lesion.
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p = 0.03), more total MACE (p = 0.06) and more stent throm-
osis (p = 0.03) in the DES ISR group.
iscussion
he main ﬁnding of this study is that regardless of the type of
tent, patients with ISR presented most often with an acute
oronary syndrome. Further, the outcome was not particu-
arly safe, with high rates of mortality and TVR—MACE at
year. Patients who had a DES ISR had a higher cardiovascu-
ar risk than patients with BMS ISR. After correction of the
linical difference between the two groups using propensity-
core matching, the outcome was not different between the
wo groups except for a trend towards more TVR in the
ES ISR group.
s ISR a signiﬁcant clinical problem?
he question of how serious restenosis is post-PCI has been
aised since the inception of the procedure. Some reports
ave suggested that ISR is not a life-threatening event and
hat it is addressed relatively easily with an additional PCI
16,17]. Some authors even thought that one does not die
rom ISR, whereas one does from stent thrombosis. Thus,
he putative increase in stent thrombosis attributable to DES
11] might not justify implantation of DES to avoid a problem
ithout clinical signiﬁcance.
Our data suggest that the presenting clinical syn-
rome is usually that of an unstable coronary syndrome
Table 1, Plot A and Fig. 1). Our data are consistent with
hose of Park et al. [18] who reported an unstable pre-
entation in 42% of patients with ISR and acute MI in 20%.
urthermore, Chen et al. [14] found that in patients with
MS ISR, 9.5% presented with acute MI, 26.4% presented with
nstable angina requiring hospitalization before angiogra-
hy and only 64.1% presented with exertional angina. Taken
ogether with our data, it is reasonable to conclude that an
nstable presentation is typical of ISR, regardless of the type
f stent, and that an unstable syndrome implies a greater
otential for lethal or disabling consequences [15].
Regarding the outcome at 1 year, our data show that the
ccurrence of adverse cardiac events is equally signiﬁcant
26.3%) as is the mortality rate (5.7%). A 5.7% risk of death
fter PCI for ISR is higher than the rate reported currently
fter PCI in a general setting, which is around 2% [19]. In
ine with a recent study [15], our results tend to prove that
SR can inﬂuence the outcome of patients, including mortal-
ty. This consideration may help to explain why there is no
ifference in mortality in large studies comparing DES and
MS. The risk of mortality and MI associated with ISR or its
anagement could balance any risk imposed by the putative
ncrease in stent thrombosis attributable to DES [20].
s BMS ISR different from DES ISR?
he clinical presentation of ISR after DES deployment
iffered from that encountered after BMS implantation
Table 1, Plot A). Patients with ISR after DES had signiﬁ-
antly more stable angina (30.9% versus 19.1%, p < 0.001)
nd more acute MI (4.3% versus 1.6%, p < 0.001) than those
ith BMS ISR. It is tempting to speculate that the higher rate
C
T
n
tA. De Labriolle et al.
f acute MI at presentation resulted from a more rapid pro-
ression of the restenosis, perhaps linked in some way to
he presumed greater propensity of the DES for stent throm-
osis. On the other hand, because there are fewer ISRs in
ES-treated patients, the proportion of more rapidly pro-
ressing obstruction, the presumed pathogenesis of MI in
SR, becomes greater. Further, patients with DES ISR had a
igher cardiovascular risk proﬁle, more often with hyperten-
ion, hypercholesterolaemia, obesity or renal insufﬁciency
t admission. All of these conditions could create a greater
rigger for inﬂammation and thrombosis [21].
Our data suggest that outcomes of PCI for ISR are very
imilar whether the ISR occurred in a BMS or a DES. Indeed,
he risk-adjusted mortality and Q-wave MI rates were indis-
inguishable up to 1 year and there was a trend only for a
reater MACE in the DES ISR group (Table 3, Plot B). On the
ther hand, the TVR rate by 1 year was signiﬁcantly greater
n patients in whom a DES was deployed at the initial proce-
ure (p < 0.05). Thus, as our results suggest (Table 3, Plot B),
t is possible that a patient who develops ISR despite place-
ent of a DES has a greater risk of a stent thrombosis than a
imilar patient with BMS, which is already known for de novo
esions. However, patients with DES ISR were treated less
requently with IIb/IIIa inhibitors — a treatment that could
mprove the outcome in ISR [22].
nterventional strategies
n our registry, operators used somewhat different strate-
ies for the management of ISR, according to the nature
f the index stent (Table 2, Plot A). This relates, at least
n part, to the fact that most BMS patients were treated
efore the release of the DES. With this in mind, it is clear
hat patients with BMS ISR were treated more often with
n ablative device. This could reﬂect a more diffuse or
roliferative pattern of ISR after BMS [23,24]. After adjust-
ent, management remained somewhat different between
he two groups (Table 2, Plot B). Regardless of any differ-
nces in treatment strategies and apart from the possibility
f a greater frequency of stent thrombosis when ISR followed
ES implantation, the in-hospital and intermediate-term
utcomes were similar.
imitations
ur study is a retrospective analysis and is subject to the lim-
tations inherent in this type of clinical investigation. The
resentation of ISR as an unstable entity could have been
verestimated due to the fact that the study population was
omposed of patients hospitalized for ISR. Patients with an
symptomatic or stable presentation who did not require
ospitalization were therefore not considered. Despite the
ropensity matching of the population, there were some dif-
erences in the management of the two groups which could
ave affected the results.onclusions
he clinical presentation of ISR is most often an acute coro-
ary syndrome. Although less life threatening than stent
hrombosis, ISR is associated with greater morbidity and
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mortality than is expected currently in patients undergoing
elective PCI. Furthermore, our data suggest that patients
with ISR after DES implantation could have a greater risk of
TVR than those whose initial stent was a BMS, possibly driven
by more stent thrombosis.
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